Advanced, effective and safe products and systems for fertility treatment

Facts as of March 31, 2022
NET SALES
January-March 752 Msek
EBIT
January-March 133 Msek
ACQUISITION
TIME
2010 via Skanditek
BURE'S OWNERSHIP STAKE
15.9 %
REPRESENTATION
FROM BURE
Henrik Blomquist (Member of the board)
NET ASSET VALUE
6 703 Msek
SHARE OF BURE'S NET ASSET VALUE
38.6 %

Vitrolife is an internationally active medical technology group. Vitrolife develops, produces and markets products for fertility treatment.

Vitrolife has approximately 400 employees, with its head office in Sweden and additional facilities and production facilities in more than ten countries worldwide.

Vitrolife has identified five strategic focus areas:

  • Sustainable, competent and scalable global organisation with a focus on sustainable processes and shared values.
  • Strong sales and support channels with the ability to offer customers customised solutions.
  • Competitive and complete product portfolio with leading support and service offering.
  • Innovative research and development, as well as efficient production and effective processes.
  • Utilises external growth opportunities for example, through strategic collaborations and acquisitions.


Vitrolife shares are listed on the NASDAQ Stockholm, Nordic Large Cap.